MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

TFEB

Search medical newsFind research, conditions and clinical updates
  • Home
  • TFEB
Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting Lipid Homeostasis
Posted inDiabetes & Endocrinology Nephrology news

Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting Lipid Homeostasis

Posted by By MedXY 10/07/2026
This study reveals how liver-sourced apolipoprotein J worsens diabetic kidney disease by impairing lipid regulation via TFEB pathways, highlighting a novel therapeutic target, MK53, for managing diabetic renal injury.
Read More
Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting TFEB-Mediated Lipid Regulation
Posted inDiabetes & Endocrinology Nephrology news

Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting TFEB-Mediated Lipid Regulation

Posted by By MedXY 10/05/2026
This study reveals that liver-secreted apolipoprotein J accumulates in renal tubules, disrupting TFEB-mediated lipid homeostasis and exacerbating diabetic kidney disease, highlighting a novel therapeutic target with the ApoJ antagonist MK53.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Navigating Parental Refusal of Optimal Pediatric Cancer Treatments: Ethical Nuances of Trust and Nudging in Clinical Care
  • Ultrasound-Detected Presynovitis Predicts Rheumatoid Arthritis Onset in ACPA-Positive Individuals
  • Operationalizing Cardiac Xenotransplantation: A Comprehensive Administrative Playbook for Clinical Implementation
  • Brepocitinib Shows Promising Efficacy and Safety in Cutaneous Sarcoidosis: Results from a Phase 2 Randomized Clinical Trial
  • Evaluating the Impact of Timing on Cleft Palate Closure Outcomes: Insights from a Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top